CD22-directed Antibody Interactions

CD22-directed Immunoconjugate

Precursor Cell Lymphoblastic Leukemia-Lymphoma

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11. DESCRIPTION</h1><p class="First">Inotuzumab ozogamicin is a CD22-directed antibody and cytotoxic-drug conjugate (ADC) consisting of 3 components: 1) the recombinant humanized immunoglobulin class G subtype 4 (IgG4) kappa antibody inotuzumab, specific for human CD22, 2) N-acetyl-gamma-calicheamicin that causes double-stranded DNA breaks, and 3) an acid-cleavable linker composed of the condensation product of 4-(4'-acetylphenoxy)-butanoic acid (AcBut) and 3-methyl-3-mercaptobutane hydrazide (known as dimethylhydrazide) that covalently attaches N-acetyl-gamma-calicheamicin to inotuzumab. </p><div class="Figure"><a name="id1541"></a><img alt="Chemical Structure" src="besponsa-01.jpg"/></div><p>Inotuzumab ozogamicin has an approximate molecular weight of 160 kDa. The average number of calicheamicin derivative molecules conjugated to each inotuzumab molecule is approximately 6 with a distribution from 2–8. Inotuzumab ozogamicin is produced by chemical conjugation of the antibody and small molecule components. The antibody is produced by mammalian (Chinese hamster ovary) cells, and the semisynthetic calicheamicin derivative is produced by microbial fermentation followed by synthetic modification. </p><p>BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial delivers 0.9 mg inotuzumab ozogamicin. Inactive ingredients are polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg). After reconstitution with 4 mL of Sterile Water for Injection, USP, the final concentration is 0.25 mg/mL of inotuzumab ozogamicin with a deliverable volume of 3.6 mL (0.9 mg) and a pH of approximately 8.0. </p></section>

Besponsa

inotuzumab ozogamicin

inotuzumab ozogamicin 0.9 MG Injection

inotuzumab ozogamicin 0.9 MG Injection [Besponsa]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Pharmacy List 

How To Order Besponsa 

Submit MSL Request 

Reimbursement Information 

Coverage Authorization Request 

Coverage Authorization Appeal

Letter of Medical Necessity 

Formulary Exception Letter 

Other HCP Resources: Access 

Billing And Coding Guide: Hospital Outpatient

Billing And Coding Guide: Physician's Office

Pfizer Oncology Together Form 

Pfizer Oncology Together Form - Spanish

Enroll in Patient Savings Program 

Pfizer Patient Assistance Program 

Free 90-day Supply: For Uninsured Patients While Applying for Medicaid

Other HCP Resources: Videos

Other HCP Resources 

About Besponsa 

Receiving Besponsa 

Side Effects 

Patient Resources 

Pfizer Oncology Patient Access Guide 

Pfizer Oncology Patient Access Guide - Spanish 

Patient Brochure 

Instructions For Use: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL)

NCCN Guidelines 

PA Checklist 

Appeals Checklist 